Association publication cites NACDS as a top lobbying group
WASHINGTON The leading biweekly newsletter on associations and non-profits recognized the National Association of Chain Drug Stores as a top lobbying association, the NACDS announced Thursday.
A front-page article in the March 28 issue of CEO Update, explores how the expertise, networking and reputation of Washington’s most effective lobbyists play key roles in communicating an organization’s messages to members of Congress and across the federal government.
“CEO Update has turned to top trade group leaders and lobbying groups for their recommendations of the most effective lobbyists in Washington,” the publication stated. The article prominently featured Carol Kelly, NACDS senior vice president of government affairs and public policy.
“A top objective of NACDS over the past year has been to develop itself as one of the top lobbying trade associations in our nation’s capital,” said NACDS president and chief executive officer Steve Anderson. “Recognition of the efforts of our government affairs and public policy team by a respected and well-read publication such as CEO Update, is a testament to the leadership of NACDS, our membership, Carol Kelly and her team to ensure that the issues facing chain drug stores are heard by policy makers and elected officials.”
Mylan twarted by court in Topamax case
TITUSVILLE, N.J. The U.S. Court of Appeals for the Federal Circuit has upheld a ruling that prevents Mylan from marketing a generic version of Ortho-McNeil Pharmaceutical’s epilepsy drug Topamax, according to Reuters.
The decision was originally found in a District Court in New Jersey. Now, Mylan has to wait until the patent expires in September before launching a generic.
Topamax had sales in 2007 of over $1.8 billion.
Independents, chains team up to spread the word about e-prescribing
ALEXANDRIA, Va. On April 17, a new campaign will launch in thousands of pharmacies, aimed at informing patients about the benefits of e-prescribing and also encouraging them to tell their doctors about the technology.
Many independent pharmacies are joining the campaign, along with such big chains as CVS, Walgreens, Rite Aid, Kerr and Wal-Mart, to promote the program through in-store signs and educational material. Signage that reads “e-prescriptions filled here” and “give your prescriptions a head start” will be found on pharmacy doors and at counters.
Patients interested in learning more about the program—such as which pharmacies or physicians in their area practice e-prescribing—will be directed to the campaign’s Web site, www.LearnAboutEprescriptions.com.
To prove the worth of e-prescribing, Walgreens and SureScripts, who is providing the network for the e-prescribing pharmacies, have released a survey showing the benefits of implementing e-prescribing in a pharmacy.
According to the findings of the Walgreens/SureScripts study, prescriptions filled at pharmacies increased by 11 percent once physicians began actively using e-prescribing and that the savings for pharmacy labor costs are $1.07 for every new prescription and $0.41 for every refill due to e-prescribing.